TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Recent studies have shown that many AML LSC-specific surface antigens could be such candidates. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In mouse models reconstituted with human AML LSCs or human hematopoietic stem cells, a human TIM-3 mouse IgG2a antibody with complement-dependent and antibody-dependent cellular cytotoxic activities eradicates AML LSCs in vivo but does not affect normal human hematopoiesis. Thus, TIM-3 is one of the promising targets to eradicate AML LSCs.

Original languageEnglish
Pages (from-to)118-123
Number of pages6
JournalAnnals of the New York Academy of Sciences
Volume1266
Issue number1
DOIs
Publication statusPublished - Aug 2012

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this